本文へ移動
cccskills
無料GitHub で公開

ata-fludrocortisone-secondary-ai-against

Recommends against using fludrocortisone for mineralocorticoid replacement in patients with secondary adrenal insufficiency. Trigger phrases include: considering mineralocorticoid replacement for secondary adrenal insufficiency and secondary adrenal insufficiency patient needing mineralocorticoid replacement.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.8 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Recommend against fludrocortisone use in secondary adrenal insufficiency

STEP 1 — Gather Information

Collect confirmation of secondary AI diagnosis (low morning cortisol, low/normal ACTH, subnormal response to ACTH stimulation test), assess for signs of mineralocorticoid deficiency (persistent hypotension, hyponatremia, hyperkalemia despite adequate glucocorticoid replacement), and measure plasma renin activity and aldosterone level if available. If secondary AI is confirmed and mineralocorticoid replacement is under consideration, proceed to STEP 2.

STEP 2 — Rule In / Rule Out

Is there biochemical or clinical evidence of mineralocorticoid deficiency (e.g., refractory hypotension, serum sodium <130 mmol/L, serum potassium >5.0 mmol/L, elevated plasma renin with low aldosterone) despite optimized glucocorticoid replacement? If yes, rule out secondary AI and evaluate for primary adrenal insufficiency or other causes; if no, proceed to STEP 3.

STEP 3 — Classify or Stratify

Classify the patient as having intact mineralocorticoid function (normal electrolytes, normal renin/aldosterone) versus impaired function. If mineralocorticoid function is intact, classify as no need for fludrocortisone; if impaired, consider alternative diagnoses.

STEP 4 — Decide

Do not prescribe fludrocortisone; continue glucocorticoid replacement only, educate patient on stress-dose glucocorticoids, and monitor for adrenal crisis.

Clinical Guardrails / Mimics / Pitfalls

Do not mistake secondary AI for primary AI; fludrocortisone can cause hypertension, hypokalemia, and edema in secondary AI due to intact renin-angiotensin-aldosterone system; avoid routine mineralocorticoid replacement in secondary AI as it increases risk of over-treatment and cardiovascular complications; always verify glucocorticoid adequacy before attributing hypotension to mineralocorticoid deficiency.

Concrete Clinical Example

A 45-year-old woman with known secondary AI from a nonfunctioning pituitary adenoma presents with fatigue and mild hypotension on hydrocortisone 15 mg daily. Electrolytes show Na 135 mmol/L, K 4.2 mmol/L, and plasma renin is normal. She does not require fludrocortisone; her hypotension resolves with increasing hydrocortisone to 20 mg daily.

Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する